A
Andrew M. Hall
Researcher at University of Zurich
Publications - 89
Citations - 3305
Andrew M. Hall is an academic researcher from University of Zurich. The author has contributed to research in topics: Medicine & Mitochondrion. The author has an hindex of 26, co-authored 77 publications receiving 2549 citations. Previous affiliations of Andrew M. Hall include University College London & Royal Free London NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
TL;DR: The nature and extent of TDF-associated kidneyoxicity in the HIV-infected population, potential underlying mechanisms of toxicity in the proximal tubule, and risk factors for developing tubular dysfunction are discussed and suggested strategies to monitor patients on TDF therapy are suggested.
Journal ArticleDOI
Tenofovir-associated renal and bone toxicity
Clare L. N. Woodward,Andrew M. Hall,Ian Williams,Sara Madge,Andrew Copas,Devaki Nair,Simon Edwards,Margaret Johnson,John O. Connolly +8 more
TL;DR: The clinical presentation and renal and bone abnormalities in a case series of HIV‐infected patients receiving treatment with tenofovir (TDF) are described and appropriate screening for toxicity related to TDF is recommended.
Journal ArticleDOI
Spectroscopic photoacoustic imaging of lipid-rich plaques in the human aorta in the 740 to 1400 nm wavelength range.
TL;DR: Spectroscopic photoacoustic imaging has the potential to discriminate between normal and lipid-rich atheromatous areas of arterial tissue by exploiting the differences in the absorption spectra of lipids and normal arterIAL tissue in the 740 to 1400 nm wavelength range.
Journal ArticleDOI
In vivo multiphoton imaging of mitochondrial structure and function during acute kidney injury
TL;DR: Real-time changes in mitochondrial structure and function can be imaged in rodent kidneys in vivo using multiphoton excitation of endogenous and exogenous fluorophores in response to ischemia-reperfusion injury or drug toxicity.
Journal ArticleDOI
Drug-induced renal Fanconi syndrome
TL;DR: Patients at risk of kidney function are monitored with more appropriate tests, and drugs should be stopped or reduced in dose if toxicity occurs, because commonly used tests for PT toxicity are not sensitive markers of PT toxicity.